275 research outputs found
A self-configuring control system for storage and computing departments at INFN-CNAF Tierl
The storage and farming departments at the INFN-CNAF Tier1[1] manage approximately thousands of computing nodes and several hundreds of servers that provides access to the disk and tape storage. In particular, the storage server machines should provide the following services: an efficient access to about 15 petabytes of disk space with different cluster of GPFS file system, the data transfers between LHC Tiers sites (Tier0, Tier1 and Tier2) via GridFTP cluster and Xrootd protocol and finally the writing and reading data operations on magnetic tape backend. One of the most important and essential point in order to get a reliable service is a control system that can warn if problems arise and which is able to perform automatic recovery operations in case of service interruptions or major failures. Moreover, during daily operations the configurations can change, i.e. if the GPFS cluster nodes roles can be modified and therefore the obsolete nodes must be removed from the control system production, and the new servers should be added to the ones that are already present. The manual management of all these changes is an operation that can be somewhat difficult in case of several changes, it can also take a long time and is easily subject to human error or misconfiguration. For these reasons we have developed a control system with the feature of self-configure itself if any change occurs. Currently, this system has been in production for about a year at the INFN-CNAF Tier1 with good results and hardly any major drawback. There are three major key points in this system. The first is a software configurator service (e.g. Quattor or Puppet) for the servers machines that we want to monitor with the control system; this service must ensure the presence of appropriate sensors and custom scripts on the nodes to check and should be able to install and update software packages on them. The second key element is a database containing information, according to a suitable format, on all the machines in production and able to provide for each of them the principal information such as the type of hardware, the network switch to which the machine is connected, if the machine is real (physical) or virtual, the possible hypervisor to which it belongs and so on. The last key point is a control system software (in our implementation we choose the Nagios software), capable of assessing the status of the servers and services, and that can attempt to restore the working state, restart or inhibit software services and send suitable alarm messages to the site administrators. The integration of these three elements was made by appropriate scripts and custom implementation that allow the self-configuration of the system according to a decisional logic and the whole combination of all the above-mentioned components will be deeply discussed in this paper
Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist
Squamous cell carcinoma is the most common malignant tumour of the head and neck. The initial TNM staging, the evaluation of the tumour response during treatment, and the long-term surveillance are crucial moments in the approach to head and neck squamous cell carcinoma (HNSCC). Thus, at each of these moments, the choice of the best diagnostic tool providing the more precise and larger information is crucial. Positron emission tomography with fluorine-18 fludeoxyglucose integrated with CT (F-18-FDG-PET/CT) rapidly gained clinical acceptance, and it has become an important imaging tool in routine clinical oncology. However, controversial data are currently available, for example, on the role of F-18-FDG-PET/CT imaging during radiotherapy planning, the prognostic value or its real clinical impact on treatment decisions. In this article, the role of F-18-FDG-PET/CT imaging in HNSCC during pre-treatment staging, radiotherapy planning, treatment response assessment, prognosis and follow-up is reviewed focusing on current evidence and controversial issues. A proposal on how to integrate F-18-FDG-PET/CT in daily clinical practice is also described
Recommended from our members
Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy - An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial.
BACKGROUND
The Decipher genomic classifier (GC) has shown to independently prognosticate outcomes in prostate cancer. The objective of this study was to validate the GC in a randomized phase 3 trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy.
PATIENTS AND METHODS
A clinical grade whole-transcriptome assay was performed on RP samples obtained from patients enrolled in SAKK 09/10, a phase 3 trial of 350 men with biochemical recurrence post-radical prostatectomy randomized to 64Gy vs. 70Gy without concurrent hormonal therapy or pelvic nodal radiotherapy (RT). A pre-specified statistical plan was developed to assess the impact of the GC on clinical outcomes. The primary endpoint was biochemical progression; secondary endpoints were clinical progression and time to hormone therapy. Multivariable analyses adjusted for age, T-category, Gleason score, post-radical prostatectomy persistent prostate-specific antigen (PSA), PSA at randomization, and randomization arm were conducted, accounting for competing risks.
RESULTS
The analytic cohort of 226 patients was representative of the overall trial, with median follow-up of 6.3 years (IQR 6.1-7.2). GC (high vs. low-intermediate) was independently associated with biochemical progression (subdistribution hazard ratio [sHR] 2.26 [95% CI 1.42-3.60], p<0.001), clinical progression (HR 2.29 [95% CI 1.32-3.98], p=0.003), and use of hormone therapy (sHR 2.99 [95% CI 1.55-5.76], p=0.001). GC high patients had 5-year freedom from biochemical progression of 45% vs. 71% for GC low-intermediate. Dose escalation did not benefit the overall cohort, nor patients with lower vs. higher GC scores.
CONCLUSIONS
This study represents the first contemporary randomized controlled trial in patients treated with early SRT without concurrent hormone therapy or pelvic nodal RT that has validated the prognostic utility of the GC. Independent of standard clinicopathologic variables and RT dose, high-GC patients were more than twice as likely than lower-GC patients to experience biochemical and clinical progression and receive of salvage hormone therapy. This data confirms the clinical value of Decipher GC to personalize the use of concurrent systemic therapy in the postoperative salvage setting
- …